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Purpose: The purpose of this project was to evaluate the complications and adverse events in 
LVAD patients when comparing those using home point of care (POCT) international 
normalized ratio (INR) testing versus lab testing. Additionally, the time in therapeutic window 
for both these groups was studied. A cost benefit analysis was performed. All this data was 
compiled into a provider education evaluated by a pre and post-survey design.  
Methods: The project is a single-center study that will occur at the University of Kentucky 
Chandler Medical Center. It is a cross-sectional, pre/post-test design. Data will be collected 
retrospectively starting January 2019, and prospectively for three months starting in October 
2020. Complications and adverse events were collected through chart review. Time in 
therapeutic window (TTR) was calculated using the Rosendaal method. INR results were 
collected from the patient’s medical record. A three question pre and post-test was used to 
evaluate provider understanding of the topic.  
Results: 32 LVAD patients were evaluated for this study. Four providers completed the pre- and 
post-test with the educational video intervention. While there were more complications in the 
home point of care group, the results were not statistically significant (p=.15). Further evaluation 
of TTR yielded a higher TTR for the POCT group, however it was also not statistically 
significant (p=.17). There was also only a mild increase in provider understanding of the topic. 
Conclusion: The findings from this study indicate that more research should be done on the 
topic. While there were more complications in the POCT group, they were not significant 
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 Background & Significance 
Heart failure (HF) is a multifaceted disease process defined as “a structural or functional 
impairment of ventricular filling or ejection of blood” (Yancy et al., 2013, p. e246). From 2013-
2016, HF affected roughly 6.2 million Americans, and it is projected to increase 46% by 2030.  
Symptoms include dyspnea, fluid retention, and pulmonary/peripheral congestion. The American 
College of Cardiology (ACC) and the American Heart Association (AHA) have categorized HF 
into four stages, from least to most severe. Stage A HF indicates no structural damage to the 
heart while Stage D HF is refractory to most treatments and requires interventions including 
pacemakers, left ventricular assist devices (LVADs), or heart transplants (Yancy et al., 2013). 
Unfortunately, there is no reverse staging. Once a person advances to a new stage of HF, despite 
treatment and improvement, they are unable to revert back to previous staging. There are many 
different guideline directed medical therapies (GDMTs) for the treatment of HF, and a large 
number of patients require these advanced interventions. 
 Although heart transplantation is considered the gold standard treatment for Stage D HF, 
the number of people requiring transplantation is on the rise, prolonging individuals’ waitlist 
time. From 1987 to 2012, more than 40,000 people were waiting for heart transplants, while only 
26,000 received a transplant (Yancy et al., 2013). With roughly 50% of those patients still 
waiting for an organ, the use of mechanical circulatory support (MCS) has been shown to be a 
viable option for these patients. LVADs are continuous flow devices implanted into the failing 
heart. They support the body by assisting the left ventricle in pumping blood through the 
circulatory system (Eisen, 2019). The 8th Annual INTERMACs report showed that between 2006 
and 2016 there were 18,987 LVAD implants, with 26% of these listed for bridge to 
transplantation (BTT) and 50% listed as destination therapy (DT; Kirklin et al., 2017).  
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Decompensated HF is one of the leading causes of hospitalizations and readmissions in 
the United States (Yancy et al., 2013).  LVADs have become the standard for decompensated HF 
as either BTT or DT. Adverse events, including thrombotic and bleeding events, cause severe 
complications for LVADs. Thrombotic events are defined as an ischemic stroke, transient 
ischemic attack and pump thrombus. Bleeding events are defined as gastrointestinal (GI) 
bleeding and hemorrhagic stroke (Nassif et al., 2016).  
International normalized ratio (INR) is a blood draw lab test that examines clotting 
factors in the blood. The goal INR in LVAD patients is 2.0-3.0. According to Nassif et al. 
(2016), the ideal INR is 2.6. Patients have different INR goals based on previous complications 
such as previous bleeding or thrombus. Warfarin is a drug used to help maintain INR within 
these tight ranges (Schettle et al., 2018). Lab draws for INR must be drawn at certain intervals to 
ensure an optimal range for LVAD patients. Dionizovik-Dimanovski et al. (2015) point out that 
there must be a delicate balance of anticoagulation in these patients in order to avoid thrombotic 
and bleeding events. Home point of care testing (POCT) has been used in some patients to more 
closely monitor INR. Studies have shown that the percentage of time in the therapeutic window 
(TTR) is higher in those utilizing home POCT (Saleem et al., 2016; Dionizovik-Dimanovski et 
al., 2015; Schloglhofer et al., 2020; Bishop et al., 2014; Table 1). Home testing has become a 
more convenient way for providers and patients to control their INR.  
Cost of testing a patient’s INR is dependent on the method of testing they utilize. 
Furthermore, there are both direct and indirect costs the patient may incur. Direct costs include 
the actual testing supplies or charge to the patient. A study found that there was a $926 
difference in cost over a 2 year span when looking at point of care testing versus lab testing 
(Phibbs et al., 2016). The authors of this study also looked at indirect costs to the patient such as 
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quality of life, time spent going to the clinic, and time taken out of work. It was concluded that 
those of use POCT had a higher quality of life score than those who went to the lab.  
Furthermore, they found that those who use home POCT had 21 fewer visits to the outpatient 
clinic, leading to less time taken off work, and a decreased cost to the patient.   
Purpose 
The purpose of this project was to evaluate complications in LVADs related to home 
POC INR results and clinical lab results. The specific aims were to: 
1. Examine hemorrhagic and ischemic complications associated with home POC 
INR testing and clinical lab INR testing to evaluate a relationship between 
testing and complications. 
2. Evaluate the percentage of time in therapeutic range TTR using the Rosendaal 
method in both patients using home POC INR testing and lab testing  
3. Conduct a cost analysis to compare cost of home POC INR testing versus lab 
testing. 
Theoretical Framework 
 The Common-Sense Model of Self-Regulation (CSM) was created by Howard Leventhal 
and is defined as “the processes by which patients become aware of a health-related threat, 
navigate effective responses to the treat, formulate perceptions of the threat and potential 
treatment actions, create action plans for addressing that threat, and integrate continuous 
feedback on action plan efficacy and threat progression” (Leventhal et al., 2016).  This model 
looks at an individual’s self-management of their health and the threats that accompany it. HF 
and LVAD patients must stay in-tune with their health and understand when there are threats, 
such as hemorrhagic and ischemic complications. The CSM provides a framework to evaluate an 
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individual’s adherence to managing such threats (Leventhal et al., 2016). Each patient is 
responsible for their own health; however, practitioners must be available to help navigate the 
issues that accompany it.  
 The thought behind utilizing home POC INR testing is that participants will be able to 
immediately contact their provider with an abnormal result. Patients may be able to detect a 
complication before it becomes serious. This can also be considered recognizing a threat. If INR 
results are subtherapeutic or supratherapeutic, providers will be able to assess the situation and 
inform the patient of the best plan. In using home POC INR testing and not having to leave the 
house for weekly testing, patients feel in control of their health. This is the patient’s action plan 
for preventing threat progression and managing possible threats to their health.  
Review of Literature 
A literature review was conducted in order to synthesis the evidence regarding home 
POC INR testing and outcomes in LVAD patients. This review included multiple databases from 
the University of Kentucky Medical Center Library including InfoKat Discover, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL) and PubMed. Keywords for the search 
include, “left ventricular assist device,” “LVAD,” “heart failure,” “home POC INR,” “point of 
care INR,” “mechanical circulatory support,” “readmissions,” “hospitalization,” and “quality of 
life.” Sixty-four articles were found using these keywords. 
All articles used had to be written in English, involve humans 18 years of age and older, 
be published within the last 10 years, and be peer reviewed. Articles were excluded if they were 
full text, written before 2010, involved animals or children aged 0 years to 17 years, or were not 
written in English. After inclusion and exclusion criteria were applied, twenty articles remained, 
five of which pertained to this research (Table 1; Table 2).  
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Of the five articles that were reviewed, two showed a correlation between POCT and 
clinical venous lab testing (Dionizovik-Dimanovski et al., 2015; Schettle et al., 2018). 
Dionizovik-Dimanovski found that POCT can overestimate INR; however, the authors felt that 
the correlation between POCT and lab were still significant enough for utilization in LVAD 
patients. Alternatively, Schettle et al. (2018) performed a large multicenter study, in which they 
found that the correlation between POCT and lab testing showed no statistically significant 
overestimation in POCT.  
Additionally, four studies showed that there was an increased percentage of time in the 
therapeutic range (TTR) for those utilizing home POCT (Saleem et al., 2016; Dionizovik-
Dimanovski et al., 2015; Schloglhofer et al., 2020; Bishop et al., 2014). Saleem at al. (2016) 
found that the TTR in participants using home POCT was 52% compared to lab testing, which 
was only 36%. Bishop et al. (2014) and Schettle et al. (2018) assert that POCT is a viable option 
for LVAD patients who may not have the means to get to the lab consistently for INR testing. 
Furthermore, Saleem et al. (2016) and Schloglhofer et al. (2020) each found a significant 
decrease in hemorrhagic and thrombotic complications in LVAD patients who utilized home 
POCT. It is important to note that Bishop et al. (2014) did not find any statistically significant 
difference in complications between home POCT and lab testing.  
There are certain gaps in the literature. First, there are multiple POC machines that are 
used for INR monitoring . Of the research that reviewed the correlation between home POCT 
and lab testing, each used a different machine. For example, Dionizovik-Dimanovski et al. 
(2015) evaluated the Alere INR machine, while Schettle et al. (2018) evaluated either the Alere 
or the CoaguCheck INR machines. Furthermore, none of the articles discussed testing costs. 
Overall, there is very limited research regarding home POCT and lab testing, and the outcomes 
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associated with each. Of the studies reviewed, only one study was performed at multiple centers, 
and most had small sample sizes. However, there were still significant data showing the benefit 
of home POCT with regard to TTR and complications in the LVAD population.  
Methods 
Design 
 The aim of this study was to evaluate INR results in LVAD patients who use home POC 
testing versus clinical lab testing in order to assess complications, TTR, and cost.  The project 
was a single-center study that occurred at the University of Kentucky Chandler Medical Center. 
It was a cross-sectional, pre/post-test design. Data was collected retrospectively starting January 
2019, and prospectively for three months starting in October 2020. After data collection from 
LVAD patients, an educational presentation on the results was sent to HF providers, along with 
pre- and post-test surveys. Variables for this project included patient demographics, LVAD type, 
HF class, home or lab INR testing, TTR, readmission rates, thrombotic complications, 
hemorrhagic complications, cost, and provider education.  
Setting 
 University of Kentucky (UK) is an academic medical center enterprise located in 
Lexington, Ky. It is the largest medical center in Lexington including both in-patient care as well 
as clinics. Albert B. Chandler hospital opened in 1962 as an extension of UK Hospital and 
houses 569 beds in the acute care setting as well as 100 intensive care unit (ICU) beds. 
Additionally, the Gill Heart and Vascular Institute (GHVI), a part of UK HealthCare, is a 
nationally recognized center for the treatment of heart disease and stroke and was recognized in 
2019 as a High Performing Hospital in Heart Failure by U.S. News and World Report. The 
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Advanced Heart Failure and Transplantation program is housed within the Gill Heart and 
Vascular Institute and was the primary location for this study. 
 UK HealthCare is committed to the three pillars of academic healthcare including 
research, education, and clinical care. Their mission is to provide advanced patient care, 
strengthen local healthcare, and support research and educational needs from the university. The 
vision of UK HealthCare is to achieve national recognition as a Top 20 public academic health 
care center while developing medical therapies for Kentucky and surrounding areas (University 
of Kentucky, 2020). Finally, the university operates under five DIReCT values which include: 
diversity, innovation, respect, compassion, and teamwork. Each of these values are used to help 
guide decision making and behaviors as well as foster a work culture dedicated to patient-
centered care.  This DNP project encompassed the mission, vision, and strategic plan of UK 
HealthCare by ensuring patient safety and quality of care during the entire study. Each patient 
was treated with respect and compassion. Additionally, the project itself was an innovative 
experience that allowed the University of Kentucky to utilize resources already available to other 
academic medical centers treating patients with advanced HF.    
 Several key stakeholders contributed to the success of this project. The Advanced Heart 
Failure Team at UK HealthCare agreed to support this project in its entirety. They are committed 
to giving quality care to their patients, helping to support patients’ quality of life, and decreasing 
hospitalizations that may occur related to complications from uncontrolled INR levels. The 
results of this project could affect participants’ physical, mental, and financial well-being, 
therefore they are also stakeholders in this project. The DNP student represents the primary 
stakeholder, as she was the one responsible for data collection and evaluation. Finally, the 
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College of Nursing at the University of Kentucky was invested in the DNP student’s success and 
completion of this project and will benefit from successful outcomes. 
Sample 
 Patients who were included were those with a) end stage HF, b) implantation of an 
LVAD device including Heartware (HVAD), Heartmate II (HMII), and Heartmate III (HMIII), 
and c) the ability to speak and write in English. Those excluded from this study were those who 
were a) less than 18 years of age and b) not on systemic anticoagulation at the time of adverse 
event. The target population for this study included patients undergoing treatment for advanced 
HF within the Gill Heart & Vascular Institute clinics. This population will include HF patients 
both with and without mechanical circulatory support. MCS Coordinators identified those who 
are appropriate to participate in the study.  
 A total of 33 participants consented to this study. A retrospective chart review was 
performed form January 2019 to September 2020. Participants were then followed until February 
2021 to evaluate INR results and complications. Of these 33 patients, one was excluded due to 
not being on any anticoagulation at the time of their complication. Therefore, the final number 
included in the study was 32 patients. Furthermore, the provider education survey was sent to 53 
participants. Of these, 11 surveys were started but only four were filled out completely.  
Data Collection 
 Approval for this project was obtainted from the Institutional Review Board (IRB) at the 
University of Kentucky where the project was performed. After approval, MCS coordinators 
contacted potential participants regarding their willingness to be involved in the study. If willing, 
MCS coordinators went through informed consent and HIPAA documentation at the patient’s 
next clinic appointment. During this time, participants also filled out a demographic survey 
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(Appendix A). After informed consent and HIPAA were obtained, the primary investigator (PI) 
began the study. Due to the COVID-19 pandemic, fewer potential participants were having in-
person clinic appointments and opting for telehealth. Therefore, an IRB amendment was 
submitted for a “Waiver of Documentation of Informed Consent” and Form K “Waiver of 
HIPAA Documentation”. Both documents were approved by the University of Kentucky IRB 
and Office of Research Integrity (ORI). These waivers also applied to providers who would 
receive the educational materials created.   
 Each participant was given a unique identification number known only to the PI. This 
was done in order to protect the participant’s identity and create anonymous data. The crosswalk 
table to decode this identification number was kept on a separate spreadsheet. All information 
was kept on the University of Kentucky OneDrive behind an encrypted, password protected 
firewall. The educational video and pre/post-test surveys (Appendix B) were created in a 
streamline format through UK REDcap system. A link was created and sent to the LVAD Clinic 
List Serv that included physicians, advanced practice providers, pharmacists, and MCS 
Coordinators. Demographic data included age, gender, ethnicity, NYHA Class, and MCS device. 
Outcome variables included: patient demographics, LVAD type, HF class, home or lab INR 
testing, TTR, readmission rates, thrombotic complications, hemorrhagic complications, cost, and 
provider education. INR results were collected for each patient for the year 2020 and use to 
calculate TTR for each patient. 
Data Analysis 
 Descriptive statistics, including means, standard deviations, and frequency distributions, 
were used to summarize study variables. Time in therapeutic window was compared between 
POC meter testing and lab testing using the two sample t-test. Adverse event rates were 
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compared between groups using the chi-square test of association. Provider knowledge items 
were evaluated pre and post using the paired sample t-test. All data analysis was conducted using 
SPSS, version 25 with an alpha of .05. 
Results  
Sample Characteristics 
 A total of 32 patients were chosen for this study after removal of inappropriate 
candidates. The average age of these participants was 51.8 years (SD 14.1; Table 3).  Participants 
were primarily male (75%) with the remainder being female (25%). Caucasians made up 78.1% 
of the participants, and 21.9% were African American. Three LVAD types were studied, 
including; Heartmate 2 (25%), Heartmate 3 (34.4%), and Heartware (40.6%). The primary New 
York Heart Association (NYHA) HF class for participants was class II (46.9%), with the 
remainder as follows: class I (3.1%), class III (34.4%), and class IV (15.6%). Seventeen of the 
participants utilized home POCT (53.1%) with the remaining 15 (46.9%) participants using the 
lab to test their INR. Participants suffered from the following comorbidities: NICM (53.1%), 
ICM (34.4%), HFrEF (100%), pulmonary HTN (3.1%), CKD (40.6%), COPD (21.9%), CVA 
(21.9%), CAD (37.5%), Diabetes (40.6%), Pulmonary Edema (3.1%), HTN (71.9%), 
hyperlipidemia (37.5%), cirrhosis (9.4%), alcohol abuse (6.3%), anxiety/depression (34.4%), and 
hypothyroidism (9.4%). Four providers completed the pre-survey, educational video, and post-
survey. Their roles were attending physician (25%; Table 4), fellow physician (25%), and MCS 
coordinator (50%).  
Complications 
 Upon completion of a thorough chart review of all participants, it was determined that 
there were eight complications related to POCT (47.1%) compared to three in the lab testing 
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group (20%) with a p-value of .15 (Table 5). Statistical evaluation of all adverse events was 
completed using the chi-square test of association. Complications were broken down even 
further by category (hemorrhagic or thrombotic). Events that are considered ischemic include 
transient ischemic attacks (TIA), ischemic stroke, and pump thrombus. Three TIAs occurred 
total, two in the POCT group (11.8%) and one in the lab testing group (6.6%), with p=1. Two 
ischemic strokes occurred in the POCT group (11.8%) due to subtherapeutic INR with no events 
in the lab testing group (p=.49). One participant in the POCT group experienced a pump 
thrombus (5.9%), with zero in the lab group (p=1).  
 The hemorrhagic adverse event category includes subarachnoid hemorrhages (SAH), 
gastrointestinal bleeds (GIB), and hemorrhagic strokes. Two participants experienced SAH in the 
lab testing group (13.3%) with none in the POCT group (p=.21). Two participants experienced 
GIB (11.8%, p=.49), and one participant experienced a hemorrhagic stroke (5.9%, p=1) in the 
POCT group. There were no other complications in the lab testing group.  
Time in Therapeutic Window 
 Time in therapeutic window (TTR) was calculated using the Rosendaal method. This 
calculation evlauates the percentage of time that the patient is in their designated INR range 
based on total days and total tests. Statistical analysis was completed using the two-sample t-test. 
There were 17 participants who utilized home PCOT with 15 participants utilizing lab testing. 
The mean TTR for the POCT group was 58.3% (SD=15.6) while the mean TTR for the lab group 
was 50.3% (SD=16.6) with a p value of .17.  
Cost Analysis  
 Information for cost analysis was gathered from the durable medical equipment (DME) 
specialist utilized by the MCS and lab departments at UK. They found that the average cost for 
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home POCT testing for patients who have both private insurance and Medicare is roughly 
$20/month or $240/year (Table 8). For lab testing, the average cost for private insurance is 
$6/test. Therefore, if a patient tests roughly 50 times a year, the average cost would be $300/year. 
Alternatively, medically necessary lab tests are covered at 100% through Medicare when ordered 
by a provider.  
Provider Education  
 The link for the pre and post survey, as well as the educational video on complications, 
cost, and TTR for LVAD patients, was sent to the LVAD Clinic List Serv at the University of 
Kentucky. This included roughly 53 potential participants including attending physicians, fellow 
physicians, APPs, pharmacists, and MCS coordinators. Of the 53 potential participants, 11 
surveys were initiated but only four were completed. Demographic information can be found 
above and in Table 4. Total pre and post test scores were statistically calculated using the paired 
sample t-test. The mean total score for the pre-test was 50% (SD=19.6) while the mean total 
score for the post test was 66.8% (SD=27.4) with a p value of .39 (Table 6). 
 These data were further broken down by each question (Appendix B). The questions were 
yes/no style.  The first question evaluated complication rates in POCT and lab testing. The pre 
survey mean was 0 with the answer from all four participants stating “no” to whether POC 
testing has more complications than lab testing (Table 7). Post test scores had a mean correct 
answer of 50% with a p value of .18. The second question evaluated cost benefit. Due to 50% of 
participants answering the pre-survey questions correctly, and 50% of participants answering the 
post survey questions correctly, the p value is 1. Finally, for time in therapeutic window, 100% 





 The collected data showed more adverse events in those who used home POCT than 
those who use lab testing. However, the data did not reach statistical significance. There were 
eight participants with complications in the POCT group and three in the lab group. It is 
important to note that while these data may not yield statistically significant results, in part 
potentially due to small sample size, that there is still a higher number of participants who 
experienced adverse events in the POCT group. This is different than the original hypothesis for 
this study, which was that there would be fewer complications in the POC group than the lab 
group, based on the literature review.  
Time in Therapeutic Window  
 The time in therapeutic window also did not show a statistically significant difference 
between home POCT and lab testing (p=.17). While this may not have a statistical significance, 
it still does correlate with the original hypothesis. Home POCT is more convenient and allows 
them to have more control over their care. However, as these patients do not have to present to a 
clinic to have their labs drawn, they may miss some tests. Further study could evaluate the total 
number of tests versus total tests in range. This would allow the investigator to evaluate 
compliance in relation to time in therapeutic window.  
Cost Analysis  
 There is mixed information when looking at the cost analysis of POCT versus lab testing. 
The cost to the patient is dependent on which insurance provider the patient uses. For private 
insurance, it appears that home POCT is most cost beneficial to patients. This is because for one 
month’s worth of testing, a POC meter costs $20/month. For lab testing, the cost is roughly 
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$6/test. Therefore, the monthly cost is dependent on how many times the participant tests. If the 
participant tests five times a month this could cost $30/month. Alternatively, if the patient has 
Medicare insurance, the cost of the POC meter is the same as with private insurance. However, 
lab testing is free. In the end when it comes to cost, the patient’s comfort level, willingness to 
participate, and understanding of the machine should weigh heavily on which testing route is 
used.  
Provider Education 
 All the data were compiled into a provider educational video. This video, along with the 
pre- and post-test, were entered into the University of Kentucky REDcap system where a 
streamline link was provided. When evaluating the four providers that completed the surveys, 
there was no statistical difference in their cumulative scores (p=.39). Furthermore, the data were 
broken down into the three questions asked on the pre and post-test. For complications, no 
provider answered the question correctly. However, 50% answered it correctly post intervention, 
yielding a p of .18. The remaining two questions yielded p values of 1. None of these data are 
statistically significant. The small sample size may have contributed to this. While this survey 
link was sent to 53 people, only four responded. Furthermore, the cohort that this was sent to 
deals only with LVAD patients. They are familiar with the patient population and may be more 
familiar with the potential outcomes of this study.  
Limitations 
 There were several limitations identified during this study. The first is the small sample 
size. In the original IRB application, informed consent and HIPAA authorization would be 
gained in person during the participant’s clinic appointment. However, due to the COVID-19 
pandemic, potential participants were not keeping their in-person appointments, or they were 
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opting for telehealth visits. Due to this, an IRB addendum was submitted for waiver of 
documentation of informed consent and waiver of HIPAA authorization. This led to a small 
sample size for LVAD participants. Additionally, only four providers completed the provider 
education. This sample size was also small and may have skewed the final results. Furthermore, 
this project was conducted at a single center. Multi-center studies allow for a larger sample size. 
Next, the retrospective and prospective nature of this study, which included chart review, was a 
limitation. This study was designed primarily on events and results that were charted in the 
patient’s electronic medical record. This relied on the documentation of providers as to whether 
adverse events and INR results were entered into the chart correctly. Finally, this study was not a 
randomized controlled trial. Randomized controlled trials are the gold standard in research, and 
therefore the absence of randomization will be considered a limitation in this study.  
Recommendations for Future Research 
 This study brought up several questions that could be directed towards future research. 
First, as there were more complications with those using home POCT, it may be beneficial to 
study the time it takes those patients to receive their warfarin dose adjustment. Also, it would be 
beneficial to look at the long-term outcomes of those who experienced adverse events in each 
group. Furthermore, additional research is needed on the reliability of home POCT. While a 
majority of the studies that have been performed found that POCT accurately correlates with lab 
testing, only a mild to moderate correlation was found between the two when results were >4.5 
(Wool, 2018). More research is needed on how comorbidities affect home POCT and lab testing. 
Participants with underlying diseases affecting their coagulation may also affect their POC INR 
results. Additionally, those diseases may also affect their adverse events and outcomes. Finally, a 
more in-depth study should be conducted regarding indirect costs to the patient. Indirect costs 
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include patient’s quality of life, time off work, and caregiver’s time. Considerations must be 
made for the patient. If the patient has to take time off work, this is time they are not getting paid 
for thus an additional cost they will incur. Additionally, it is important to look at a possibility of 
improved quality of life for those patients who use home testing equipment.  
Conclusion 
 This study produced different outcomes than originally hypothesized. While none of the 
data were statistically significant, there were clinically significant findings. Despite having more 
control over their testing and having a higher percentage of time in their therapeutic window, 
participants who utilized home POCT experienced more adverse events than the lab testing 
group. Additionally, providers experienced an increase in knowledge when it came to their 
understanding of adverse events in the home POCT group. Furthermore, cost to the patient is 
highly dependent on the insurance they use, their understanding of the equipment, and their 
willingness. This should be considered when making a decision about testing. It is important to 
broaden this study to multiple centers in efforts to gather a larger sample population. 
Comorbidities should also be evaluated to understand their effect on certain outcomes as well as 
looking at the long term outcomes of those who do experience adverse events. Finally, further 
research is needed on the number of tests in range compared to the number of tests administered 
when examining TTR. This would provide a better picture of a patient’s compliance with testing 
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Table 1. Literature review  
 
Author, Year  Study Design  




Main Findings   Level of 
Evidence   
Saleem et al. 
(2016)  
Retrospective   
  
To evaluate complications in 
LVAD patients using 
home INR testing versus lab 
testing. Complications were 
defined and thrombotic or 
hemorrhagic events  
42 patients (26 
home testing, 16 
lab testing)   
  
Single center 
study   
Patients who 
use home testing, 
tested fewer times 
than patients who 
used the lab   
  
52% of patients 
who used home 
testing were within 
range  
  
36% of patients 
who used lab 
testing were within 
range   
  
Patients who used 
home testing had 
fewer hemorrhagic 
complications (15% 




al., (2015)  
Prospective, correlation 
study   
  
To determine the reliability 
of the Alere point of care 
machine versus clinical lab 
testing in patients with CF-
LVADs  
50 patients with 
LVADs on 
stable warfarin 
therapy for at 
least 3 weeks   
  
Single center 
study   
 Alere device 
consistently 
overestimate INR   
  
Home INR testing 
is more convenient 
and improves the % 
of time within 
targeted INR 









al., (2020)  
Retrospective Review   
  
To evaluate if frequency of 
point of care INR 
48 LVAD 
patients who use 
point of care 
INR testing  
The % of INR 
within range was 
higher in those who 
  
 28 
testing effects the quality of 
anticoagulation therapy, 
adverse events, and 




tested 3 times a 








INR had lower 
thrombotic and 
hemorrhagic 
events   
Bishop et al., 
(2014)  




evaluate effectiveness patient 
self INR testing versus lab 
testing in LVADs  
55 LVAD 
patients (44 lab 
testing, 11 self 
testing)   
 
Single center 
study   
% of time within 
targeted range was 






between the two 
groups  
  






To determine whether POC 
INR versus plasma INR INR 
values differ in the LVAD 
population   
279 patients 
with LVADs  
  
7 centers, 
internationally   
No statistical 
difference between 
POC verses plasma 
INR 




patients with and 













Table 2. Synthesis table to summarize findings 








al., (2015)  
Schloglhofer et 
al., (2020)  
Bishop et al., 
(2014)  




(POCT vs lab)  
↓c  NE  ↓b  ND (b)  NE  
Thrombotic 
complications 
(POCT vs lab)  
↓c  NE  ↓b  ND (b)  NE  
TTR in POCT  ­c  ­c  ­b  ­b  NE  
Correlation of 
POCT and lab  
NE  ­b  NE  NE  ­b  
LEGEND: ­=INCREASED; ¯=DECREASED; NE=not evaluated; ND=no difference; 
POCT=point of care testing; TTR=% time in therapeutic range; a higher 

























Table 3. Descriptive summary of patient demographic and clinical characteristics (N =32) 
 
Characteristic Mean (SD) n (%) 
Age 51.8 (14.1) 
Gender 
   Male 





  Caucasian 









  Heartmate 2 
  Heartmate 3 






  Class I 
  Class II 
  Class III 







  POC Meter 





  NICM 
  ICM 
  HFrEF 
  pHTN 
  CKD 
  COPD 
  CVA 
  CAD 
  DM 
  Pulmonary Edema 
  HTN 
  HLD 
  Cirrhosis 
  Alcohol Abuse 
  Anxiety/Depression 
























Table 4. Descriptive summary of provider characteristics (N=4) 
Characteristic Mean (SD) n (%) 
Provider Type 
  Attending 
  Fellow 







Table 5. Outcomes for POCT and Lab Testing 
 Meter 
(n =17) 
mean (SD) or n (%) 
Lab 
 (n = 15) 
mean (SD) or n (%) 
p 
Time in therapeutic 
window 
58.3% (15.6) 50.3% (16.6) .17 
Adverse event 
  Yes 
  No 
 
  TIA 
  Ischemic Stroke 
  Pump Thrombus 
  Subarachnoid 
Hemorrhage 
  GIB 































    
 
Table 6. Provider Cumulative Pre-Post Test Scores 
 
































Table 7. Provider Pre-Post Test Scores by Question (n=4) 





Complications 0 (0)  50%  .18 
Cost 50%  50%  1 
TTR 100%  100%  1 
 
 
Table 8. Cost  
 POC Meter Lab 
Private Insurance $240/year $6/test 



















Appendix A. Demographic Survey 
Demographic Survey  
 




d. Prefer not to answer 
 
2. What is your age? 
a. __________ 
 
3. Please specific your ethnicity 
a. Caucasian 
b. African-American 
c. Latino or Hispanic 
d. Asian 
e. Native American 
f. Native Hawaiian or Pacific Islander 
g. Two or More 
h. Other/Unknown 
i. Prefer not to answer 
 









h. Prefer not to say 
 
5. What is your New York Heart Association (NYHA) Heart Failure status? 
a. Class I - No symptoms and no limitation in ordinary physical activity, e.g. 
shortness of breath when walking, climbing stairs etc.  
b. Class II- Mild symptoms (mild shortness of breath and/or angina) and slight 
limitation during ordinary activity.  
c. Class III - Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20—100 m).Comfortable only at 
rest. 
d. Class IV- Severe limitations. Experiences symptoms even while at rest. Mostly 
bedbound patients.  
e. No NYHA class listed or unable to determine. 
 
6. Do you have a mechanical circulatory device? 
a. Heartware 
b. HeartMate II 












Appendix B. Pre and Post Test 




1. Does point of care (POC) INR testing correlate to more thrombotic or hemorrhagic 
complications when compared to clinical lab INR testing? 
a. Yes 
b. No 




3. Do patients utilizing POC INR have a higher percentage of time in their therapeutic 
(TTR) window? 
a. Yes 
b. No 
 
